hari kishan boorugu

Dr. hari kishan boorugu


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2013 in Tropical Doctor
Verified
Journal Article
Closed access
HBhari kishan boorugu
hari kishan boorugu
ACAnugrah Chrispal
Anugrah Chrispal
KGKg Gopinath
Kg Gopinath
SCSara Chandy
Sara Chandy
JPJohn Jude Prakash
John Jude Prakash
KTKurien Thomas
Kurien Thomas
Scrub typhus is an emerging infectious disease in India. Among its protean clinical manifestations, central nervous system involvement is common. In this prospective observational study, altered sensorium, headache, seizures and aseptic meningitis were found to be common central nervous system manifestations. Prompt treatment with doxycycline reduces morbidity and mortality.


1 January 2012 in Indian Journal of Critical Care Medicine
Verified
Journal Article
Open access
PDF file
HBhari kishan boorugu
hari kishan boorugu
ACAnugrah Chrispal
Anugrah Chrispal
Cartap hydrochloride, a nereistoxin analog, is a commonly used low toxicity insecticide. We describe a patient who presented to the emergency department with alleged history of ingestion of Cartap hydrochloride as an act of deliberate self-harm. The patient was managed conservatively. To our knowledge this is the first case report of Cartap hydrochloride suicidal poisoning. Cartap toxicity has been considered to be minimal, but a number of animal models have shown significant neuromuscular toxicity resulting in respiratory failure. It is hypothesized that the primary effect of Cartap hydrochloride is through inhibition of the [ 3 H]-ryanodine binding to the Ca 2+ release channel in the sarcoplasmic reticulum in a dose-dependent manner and promotion of extracellular Ca 2+ influx and induction of internal Ca 2+ release. This results in tonic diaphragmatic contraction rather than paralysis. This is the basis of the clinical presentation of acute Cartap poisoning as well as the treatment with chelators namely British Anti Lewisite and sodium dimercaptopropane sulfonate.

1 September 2021 in Indian Heart Journal
Verified
Journal Article
Open access
PJPankaj Jariwala
Pankaj Jariwala
KJKartik Pandurang Jadhav
Kartik Pandurang Jadhav
APArshad Punjani
Arshad Punjani
HBhari kishan boorugu
hari kishan boorugu
AMAjay Reddy Mari
Ajay Reddy Mari
Objectives: We evaluated the efficacy and safety of dapagliflozin, a SGLT2i along with ARNI in refractory HFrEF irrespective of their diabetic status. Methods: We performed a retrospective analysis of 104 symptomatic patients of HFrEF despite of optimal medical management with ARNI between January-June 2020. Despite the optimal GDMT, dapagliflozin, SGLT2i was added inpatients withrefractory heart failure. At 6-months follow-up, the primary outcome was change in left ventricular ejection fraction, and secondary outcomes included changes in NYHA functional class, vital parameters, renal function, potassium levels, and NT-pro BNP levels. Results: The primary outcomeat 6-months follow-up was a mean change in left ventricular ejection fraction (LVEF) +9.00 +/- 0.62 (p < 0.001). The secondary outcome was a significant improvement (69%) in median NYHA functional class by 2.3 (95% Confidence interval 2.245-2.355) with 92.6% of patients were in NYHA class I and 7.4% were in NYHA class II.Diabetic subgroup reached the HbA1C goal of <7%. None of them had either symptomatic hypotension, hypoglycaemia, dyselectrolaemia, and decline in renal function. The drug was well received by most of the patients. Conclusions: Dapagliflozin, an SGLT2i, should be used in symptomatic, refractory HFrEF patients despite the use of ARNI. The combination of ARNI and SGLT2i is well tolerated, but large, randomized trials are needed to prove this hypothesis. (C) 2021 Cardiological Society of India. Published by Elsevier B.V.

13 June 2024 in Indian Heart Journal
Verified
Journal Article
Open access
PJPankaj Jariwala
Pankaj Jariwala
GKGururaj Pramod Kulkarni
Gururaj Pramod Kulkarni
APArshad Punjani
Arshad Punjani
HBhari kishan boorugu
hari kishan boorugu
DGDilip Gude
Dilip Gude
We evaluated empagliflozin in severe DAS patients with HF before AVR. HF patients with LVEF 30-80 % and NYHA functional class II-IV symptoms got empagliflozin 10 mg or not within 6 months before AVR, along with SOC. Adding empagliflozin to the SOC before AVR reduced HF death or HHF by 73 % after 6-months in a group of 20 patients (RR 0.27; p = 0.022). Improving LVEF (+3.48 %, p < 0.001) and NT-proBNP levels (-3974.6 pg/mL) with empagliflozin in SOC before AVR significantly reduced in-hospital and 6-month mortality in this patient group. In severe DAS and HF patients, empagliflozin improved symptoms and prognosis.

1 November 2009
Verified
Journal Article
Closed access
ACAnugrah Chrispal
Anugrah Chrispal
HBhari kishan boorugu
hari kishan boorugu